Revance Highlights DAXXIFY, SkinPen and New Skincare Launches at AAD 2026 — What Dermatologists Should Expect

Table of Contents

  1. Key Highlights:
  2. Introduction
  3. Revance’s renewed dermatology push: strategic aims and on-site programming
  4. What’s on display: injectables, microneedling and resilient hyaluronic acid
  5. Consumer skincare rollout: bridging professional care and at-home maintenance
  6. How the AIRE Health partnership reframes physician-brand collaboration
  7. Booth talks: what clinicians can expect to learn and apply
  8. Safety spotlight: DAXXIFY® boxed warning and clinical counseling
  9. Microneedling in contemporary practice: SkinPen®’s role and clinical evidence
  10. Teoxane RHA® Collection and practical filler application strategies
  11. How dermatology practices can prepare for integrating Revance products
  12. Market implications: competition, patient demand and the convergence of clinical and consumer channels
  13. Practical case examples: how clinics might implement the new offerings
  14. Evaluating evidence and patient communication
  15. What to watch after AAD: adoption signals and follow-up resources
  16. FAQ

Key Highlights:

  • Revance will present a broad slate of aesthetics, regenerative and consumer skincare innovations at the American Academy of Dermatology Annual Meeting (March 27–31, 2026, Denver), including product demos, expert-led booth talks, and a strategic partnership with AIRE Health.
  • Clinical programming centers on DAXXIFY® injectable treatments, SkinPen® microneedling, and the Teoxane RHA® Collection; the company will also introduce new consumer skincare SKUs across PanOxyl®, Blue Lizard®, StriVectin® and other brands, distributing samples at Booth #3732.
  • Safety and regulatory guidance for DAXXIFY® is emphasized: approved for temporary improvement of moderate to severe glabellar lines in adults, with detailed boxed-warning and adverse-effect counseling included in Revance materials.

Introduction

The American Academy of Dermatology Annual Meeting consistently serves as both a launch pad and a crossroads where clinical evidence, device innovation, and consumer skincare trends converge. Revance chose this forum to stage a visible reassertion of its dermatology focus, bringing a lineup that spans prescription injectables, microneedling technology, hyaluronic acid filler strategies, and a refreshed consumer skincare roster. The company’s presence combines scientific presentations with hands-on demonstrations and physician-centered networking—elements that influence how dermatology practices evaluate, adopt, and integrate new treatments.

Revance’s exhibit program arrives at a time when dermatologists prioritize multi-modality treatment plans, seek tighter evidence on safety and durability, and look for consumer brands that support in-office protocols. The move also reflects an industry shift: companies no longer present devices and prescription drugs in isolation; they pair professional interventions with consumer-facing products designed to extend treatment benefits and enhance patient loyalty. The announcements and programming at Revance’s Booth #3732 will offer a concentrated view of that strategy.

What follows is a detailed look at Revance’s AAD activities, the clinical and commercial context around the featured products, practical implications for dermatology practices, and answers to the questions clinicians and patients are likely to raise.

Revance’s renewed dermatology push: strategic aims and on-site programming

Revance is positioning this AAD appearance as more than a marketing exercise. CEO Nadeem Moiz framed the company’s objective in direct terms: to showcase progress across aesthetics, regenerative and skincare portfolios and to emphasize science-driven innovation. That statement signals a deliberate attempt to address the full patient journey—from in-clinic procedural outcomes to at-home maintenance.

The on-site program is organized around three complementary goals:

  • Educate clinicians on new clinical insights and techniques linked to Revance products.
  • Provide hands-on experience and live discussion through booth talks with recognized dermatology leaders.
  • Strengthen relationships with dermatologists and industry partners via curated networking events and a partnership with AIRE Health.

Booth talks will feature a mix of clinical and practical topics. Presenters include Diane Berson, MD (DAXXIFY® and Teoxane RHA Collection), Michael Gold, MD (SkinPen® microneedling), Ava Shamban, MD (DAXXIFY®), Jody Comstock, MD (Teoxane RHA® Collection and the Multilayering Technique), and Suneel Chilukuri, MD (SkinPen®). Each session is scheduled during the conference and designed for succinct clinical takeaways that translate into in-clinic practice.

Revance’s collaboration with AIRE Health introduces another dimension. AIRE Health is a physician-founded platform focused on technology-enabled brand collaborations; its involvement suggests Revance will emphasize how dermatologists can legitimately and productively partner with brands while maintaining clinical independence and ethical standards. The invite-only offsite reception in Denver will convene leading clinicians and innovators, a forum where new collaborations and practice-level implementation strategies frequently take shape.

What’s on display: injectables, microneedling and resilient hyaluronic acid

Revance’s exhibit content divides into three professional categories: botulinum toxin injectables (DAXXIFY®), microneedling devices (SkinPen®), and hyaluronic acid fillers (Teoxane RHA® Collection and the Multilayering Technique). Each item has its own clinical evidence base and typical use patterns.

DAXXIFY® (daxibotulinumtoxinA-Ianm) DAXXIFY®, approved for temporary improvement of moderate to severe glabellar lines in adults, represents Revance’s flagship injectable for aesthetic neuromodulation. The product’s clinical profile emphasizes duration of effect and safety considerations, and the company will use AAD to reassert those attributes. Clinic adoption decisions hinge on durability claims, comparative dosing and patient selection. Revance is clear that DAXXIFY® dosing units are not interchangeable with other botulinum toxin products—an operational point practices must manage in record-keeping and patient education.

SkinPen® microneedling devices Microneedling has moved from adjunctive therapy to mainstream procedure, supported by evidence for collagen induction, scar improvement, and enhanced topical penetration. SkinPen® appears regularly in device discussions because it is a regulated medical microneedling platform designed for standardized depth and safety controls. Booth talks by Michael Gold, MD and Suneel Chilukuri, MD will likely address procedural settings, combination protocols, and clinical outcomes across skin types.

Teoxane RHA® Collection and MLT Multilayering Technique™ Revance will spotlight the Teoxane RHA® Collection and a specific application method, the Teoxane MLT Multilayering Technique™, which aims to use different filler viscosities and resiliencies to achieve natural volumization and surface smoothing. The technique’s proponents describe it as a way to sculpt contours while preserving movement, pertinent to patient demand for natural-looking results.

These modalities are often used in combination—botulinum toxin to relax dynamic lines, fillers to restore volume and contour, and microneedling to improve skin texture and product absorption. How clinics bundle these options affects appointment scheduling, inventory, pricing, and patient counseling.

Consumer skincare rollout: bridging professional care and at-home maintenance

Revance is bringing multiple consumer skincare SKUs to the conference floor, expanding its reach beyond prescription and device markets into everyday skin health. The brands highlighted at AAD include PanOxyl®, Blue Lizard®, StriVectin®, TL Advanced, and Sarna®. Samples of new launches and established hero products will be distributed, and limited Blue Lizard scrub tops will be available for dermatologists during Exhibit Hall hours.

Why these consumer lines matter to dermatologists Clinics increasingly curate skincare regimens that extend procedure benefits and reduce complications. Acne cleansers, after-sun lotions, barrier-restoring creams, and eczema relief formulations offer direct utility in pre- and post-procedural care. For example:

  • An antimicrobial or medicated cleanser helps manage bacterial load before microneedling or certain in-office treatments.
  • A calming after-sun lotion supports barrier recovery after light-based procedures or prolonged sun exposure.
  • A barrier-repair cream reduces transepidermal water loss, which can accelerate healing after resurfacing.

These products play a dual role: they improve patient outcomes when appropriately recommended and create retail revenue streams for practices. Distributing samples on-site is a classic conference tactic to drive trial use and encourage later in-office purchases.

Product examples and positioning (general)

  • PanOxyl®: Typically positioned for acne-prone skin and office-recommended regimens that align with therapeutic intent. Dermatologists often pair medicated washes with topical or systemic therapies.
  • Blue Lizard® After Sun Soothing Lotion: Positioned to soothe sun-exposed skin and support barrier restoration, useful in patient counseling around post-procedure care.
  • StriVectin® Barrier Restore+ Soothing Ceramide Cream and Milky Mist: Positioned for barrier repair and hydration; clinicians may recommend these for patients undergoing resurfacing or as part of anti-aging maintenance.
  • TL Advanced Tightening Neck & Chest Lotion Broad Spectrum SPF 35: Emphasizes photoprotection for frequently neglected areas.
  • Sarna® Eczema Relief Skin Protectant Lotion: Positions as an over-the-counter aid for symptomatic relief of itchy, dry skin.

Offering samples at a major meeting accelerates clinician familiarity. When dermatologists can trial products before recommending them to patients, adoption rates and patient compliance historically improve. Clinics that integrate sample-driven product trials into their consultation process often see higher retail conversion.

How the AIRE Health partnership reframes physician-brand collaboration

Revance’s program with AIRE Health underscores a growing focus on formalized, ethically mindful collaborations between clinicians and companies. Founded by dermatologists Dhaval Bhanusali, MD and Muneeb Shah, MD, AIRE Health promotes technology-enabled, physician-centered initiatives. At AAD, the collaboration will focus on the evolving role of physicians in brand partnerships—an area that has grown more complex as regulatory scrutiny and patient expectations have tightened.

Key considerations when physicians engage with brands

  • Transparency: Clinicians must disclose relationships in a way that preserves patient trust and meets institutional and professional requirements.
  • Scientific integrity: Physician involvement should emphasize evidence and clinical outcomes over promotion. Education that includes data, limitations and safety profiles preserves credibility.
  • Commercial balance: Collaboration can provide clinics with access to early data, samples and co-branded patient resources. Practitioners must balance the commercial benefits with the primacy of patient welfare.

The offsite reception and invite-only programming will permit candid discussions about revenue models, ethical boundaries, and practical tools for managing collaborations—topics that shape whether partnerships translate into better care or perceived conflicts.

Booth talks: what clinicians can expect to learn and apply

Short, focused educational sessions at industry booths can be high-yield when they target procedural nuance and practical workflow. Revance’s scheduled talks map to clinician needs: technique refinement, combination therapy insights, and device optimization.

Selected sessions from Revance’s AAD booth schedule (as listed):

  • Diane Berson, MD — DAXXIFY® and Teoxane RHA® Collection (Friday, 3/27 at 12:00 PM)
  • Michael Gold, MD — SkinPen® microneedling devices (Friday, 3/27 at 12:30 PM)
  • Ava Shamban, MD — DAXXIFY® (Saturday, 3/28 at 12:00 PM)
  • Jody Comstock, MD — Teoxane RHA® Collection and the Teoxane MLT Multilayering Technique™ (Saturday, 3/28 at 12:30 PM)
  • Suneel Chilukuri, MD, FAAD, FACMS — SkinPen® (Saturday, 3/28 at 1:00 PM)

What these sessions typically offer

  • Case-based insights: Presenters often show before-and-after cases that illustrate patient selection and expected durability.
  • Technique tips: For injectables and fillers, micro-anatomical considerations, depth, and layering strategies are discussed. For microneedling, needle depth, pass counts, and adjunctive device settings are emphasized.
  • Combination protocols: Sessions typically cover how to sequence neuromodulators, fillers, and skin resurfacing to maximize safety and outcomes.
  • Post-procedural care: Speakers usually recommend topical regimens and timing for returning to normal skincare, a natural tie-in with Revance’s consumer SKUs.

Clinicians attending these talks can expect practical pearls that facilitate immediate integration into consultations and procedures.

Safety spotlight: DAXXIFY® boxed warning and clinical counseling

Revance is not sidestepping the safety conversation. DAXXIFY® carries an important safety profile that practices must navigate carefully. The company’s materials and AAD sessions will likely emphasize proper patient selection and adverse event recognition.

Key safety points provided by Revance:

  • DAXXIFY® may cause serious, potentially life-threatening side effects. Seek medical help immediately for problems with swallowing, speaking, or breathing after injection.
  • Effects may spread from the injection site and cause muscle weakness, double vision, blurred vision, drooping eyelids, hoarseness or changes in voice, trouble saying words clearly, loss of bladder control, and respiratory problems.
  • Do not administer DAXXIFY® if the patient is allergic to any ingredients or has had an allergic reaction to other botulinum toxin products.
  • DAXXIFY® dosing units are not the same as other botulinum toxin products. Clinicians must not use unit-to-unit conversion without specific guidance.
  • Patients must disclose all medical conditions, prior botulinum toxin exposures, and current medications, including supplements and over-the-counter products.
  • Report suspected side effects to Revance and to the FDA MedWatch program as instructed.

Clinical counseling implications

  • Informed consent must specifically address potential distant toxin spread and respiratory compromise, particularly in patients with pre-existing neuromuscular disorders or swallowing difficulties.
  • Documentation should record the specific botulinum toxin product administered, dose, lot number and treatment site, because cross-product confusion has clinical and pharmacovigilance consequences.
  • Scheduling and follow-up protocols should include early post-procedural checks and clear escalation pathways if patients experience adverse symptoms.

DAXXIFY® is positioned for glabellar lines, where neuromodulation is routine, but the broader safety admonitions apply to any botulinum toxin administration. Practices should use AAD sessions and Revance resources to refine pre-procedure screening and counseling scripts.

Microneedling in contemporary practice: SkinPen®’s role and clinical evidence

Microneedling technology has seen accelerated adoption because of its versatility and compatibility with other procedures. SkinPen® is a regulated microneedling device intended for creating controlled micro-injuries that stimulate collagen production and enhance topical product delivery.

Clinical contexts where microneedling is used

  • Acne scarring: Microneedling improves superficial and rolling scars through collagen remodeling.
  • Fine lines and texture: Studies and clinical experience show improvement in skin texture and reduction of fine lines after serial treatments.
  • Hyperpigmentation and melasma adjunct: When used carefully and in combination with other modalities, microneedling can improve pigmentary concerns, although practitioner caution is required in darker phototypes to avoid post-inflammatory hyperpigmentation.
  • Transdermal delivery: Microneedling enhances penetration of topical agents, which can increase effectiveness for certain active ingredients.

Integration with other modalities Clinicians frequently combine microneedling with neuromodulators and fillers, or time sessions around injectables. For example, a patient may receive a neuromodulator to soften dynamic lines and undergo microneedling for overall texture improvement; hyaluronic acid fillers may follow to address volume loss after skin texture is improved. Scheduling must account for wound healing and infection risk.

Practical considerations for clinics

  • Standardized depth and controlled device settings reduce variability in outcomes and risk.
  • Pre-procedure cleansing and post-procedure barrier support are essential. Revance’s consumer products may be positioned to support these steps.
  • Training and credentialing: Staff proficiency with microneedling devices affects outcomes, so practices must invest in competency development.

Sessions by Michael Gold, MD and Suneel Chilukuri, MD will likely address these operational details, providing actionable insights for clinicians integrating SkinPen® into their offerings.

Teoxane RHA® Collection and practical filler application strategies

The Teoxane RHA® Collection emphasizes resilience and tissue-adaptive hyaluronic acids that reportedly move with facial dynamics—an attribute that addresses patient demand for natural movement after filler therapy. The Teoxane MLT Multilayering Technique™ provides a structured approach to using different product viscoelastic properties in sequence to achieve multidimensional correction.

Clinical rationale for multilayering

  • Structural support in deeper layers with firmer gels restores volume.
  • Superficial placement of softer, more flexible gels smooths fine lines and offers surface refinement.
  • Layering can minimize lumpiness and produce a more natural transition across tissues.

Technique and risk mitigation

  • Understanding product rheology is essential to avoid overcorrection or migration.
  • Practitioners must map anatomically safe zones and be versed in vascular occlusion recognition and management.
  • Combining fillers with neuromodulators and energy-based devices requires precise timing to avoid adverse tissue reactions.

Jody Comstock, MD’s session will likely illustrate layering strategies through visual cases and procedural checklists, enabling attendees to adopt the technique responsibly.

How dermatology practices can prepare for integrating Revance products

Clinics evaluating new products must balance clinical benefit with operational realities. Revance’s booth and programming supply an entry point for evidence and practical training, but adoption depends on broader readiness.

Inventory and supply chain

  • DAXXIFY® requires separate storage and inventory tracking from other botulinum toxins due to non-interchangeable dosing units.
  • Device introductions, such as SkinPen®, demand initial capital budgeting, staff training and maintenance planning.
  • Consumer SKU rollouts necessitate shelf-space decisions, sample management and point-of-sale processes.

Clinical protocols and patient flow

  • Standardized pre-procedure screening for neuromodulators and devices helps avoid adverse events.
  • Consent forms must be updated to reflect product-specific risks and patient counseling.
  • Bundling strategies that pair in-office procedures with recommended home-care regimens improve adherence and outcomes.

Staff training and marketing

  • Nurses and injector staff require training on unique dosing and technique nuances of DAXXIFY®.
  • Patient education materials should explain differences among botulinum toxins and set realistic expectations about duration and safety.
  • Practices may use booth-provided samples as trial items for patients, then offer recommended products at checkout.

Business considerations

  • Pricing strategy should reflect expected longevity of product effects, procedural time, and comparative market options.
  • Practices may negotiate product training and co-marketing support with manufacturers to ease adoption.
  • Payment models, including package pricing for combination treatments and skincare regimens, facilitate patient uptake.

Audience at Revance’s AAD presence will gain access to tangible resources—samples, scrubs and peer-to-peer case studies—that reduce barriers to trial and adoption.

Market implications: competition, patient demand and the convergence of clinical and consumer channels

Revance’s integrated strategy reflects broader industry trends: aesthetic companies increasingly align prescription-grade and consumer offerings to create continuity between clinical procedures and daily skin health. The immediate implications for the market include:

Competitive dynamics

  • Botulinum toxin space: DAXXIFY® competes with established products such as onabotulinumtoxinA (BOTOX®), abobotulinumtoxinA (DYSPORT®), incobotulinumtoxinA (XEOMIN®) and others. Differences in duration, side-effect profiles and dosing conventions shape clinician choice.
  • Device pairing: Offering a device like SkinPen® alongside injectables allows a company to provide end-to-end solutions to clinics, potentially increasing the stickiness of partnerships.
  • Skincare retail: Bringing consumer SKUs into clinical settings blurs the lines between retail and medical recommendations, but also offers revenue diversity for practices.

Patient expectations and behavior

  • Patients increasingly seek integrated solutions that optimize both in-office procedures and at-home maintenance. They expect cohesive regimens and transparent evidence of benefit.
  • Trial through sampling at conferences or clinics often accelerates consumer loyalty. Dermatologists who curate trusted, evidence-based product selections enhance patient confidence.

Regulatory and ethical considerations

  • Physician-brand collaborations must align with disclosure guidelines and avoid undue commercial influence on clinical decision-making.
  • Safety reporting and device vigilance obligations persist alongside retail marketing efforts.

For dermatology practices, the market is shifting toward service bundles that combine procedural excellence with curated consumer products. Revance’s AAD strategies embody that shift.

Practical case examples: how clinics might implement the new offerings

Example 1: A combined approach for a 45-year-old patient with dynamic glabellar lines and early cheek volume loss

  • Initial visit: injector counsels on neuromodulator options; DAXXIFY® is presented as one option for glabellar lines, with specific discussion of expected duration and safety. Consent includes DAXXIFY®-specific warnings.
  • Adjunctive treatment: Hyaluronic acid from the Teoxane RHA® Collection is recommended for cheek contouring using a multilayering approach for natural movement.
  • Aftercare: Post-procedure, the patient receives samples of a barrier-repair cream and an after-sun soothing lotion to support skin recovery and home care.

Example 2: Acne scar management with microneedling

  • Protocol: SkinPen® microneedling serial treatments spaced 4-6 weeks apart, combined with in-office topical agents to enhance remodeling.
  • Pre-procedure: Clinic recommends a medicated cleanser sample (PanOxyl®) to reduce surface bacterial load and optimize healing.
  • Follow-up: StriVectin® barrier-focused moisturizer is recommended to support epidermal repair between sessions.

Example 3: Eczema-prone patient planning energy-based resurfacing

  • Pre-procedure: Assess baseline eczema control. Recommend Sarna® Eczema Relief for symptomatic relief where appropriate, and tailor energy settings accordingly.
  • Post-procedure: Prescribe a soothing ceramide cream to support barrier function and reduce risk of flare.

These scenarios illustrate how an integrated product portfolio supports clinical decision-making and patient outcomes. They also reveal logistical steps—product inventory, staff training and consent—that practices must address.

Evaluating evidence and patient communication

Clinicians must reconcile marketing claims with peer-reviewed evidence. For new treatments, especially in the aesthetic space, best practice includes:

  • Review of randomized controlled trials, when available, and real-world observational data to understand durability and adverse-effect profiles.
  • Transparent discussions with patients about what is known and where evidence is still emerging.
  • Clear documentation of product-specific considerations such as non-interchangeable dosing units and contraindications.

Patient conversations should be concise, fact-focused and oriented toward expected outcomes, recovery timeline, and safety measures. For example, when discussing DAXXIFY®, outline the approved indication (glabellar lines), emphasize reporting pathways for adverse effects, and document any previous exposure to botulinum toxins.

What to watch after AAD: adoption signals and follow-up resources

After the conference, adoption patterns typically reveal themselves through several signals:

  • Practice-level trialing: Early adopters will publish case series, social channels and peer networks documenting outcomes.
  • Product availability and training: Widespread device onboarding and distribution of DAXXIFY® samples indicate readiness.
  • Patient demand: An increase in patient inquiries tied to conference visibility often drives early adoption.

Clinicians should look for:

  • Post-AAD webinars and training modules from Revance and AIRE Health that expand on booth material.
  • Peer-reviewed publications or post-market surveillance updates clarifying long-term safety and efficacy.
  • Practice-level outcome tracking to assess whether interventions meet expectations in diverse patient populations.

Revance’s AAD presence is a preview; the subsequent months will determine whether these offerings materially change clinical practice patterns.

FAQ

Q: When and where is Revance exhibiting at the AAD Annual Meeting? A: Revance is exhibiting at the American Academy of Dermatology Annual Meeting, March 27–31, 2026, in Denver, Colorado. Visit Booth #3732 for product demonstrations, samples and scheduled booth talks.

Q: What are the primary products Revance is highlighting at AAD? A: Revance’s featured professional offerings at AAD include DAXXIFY® (daxibotulinumtoxinA-Ianm) injectable for glabellar lines, SkinPen® microneedling devices, and the Teoxane RHA® Collection with the MLT Multilayering Technique™. The company is also presenting consumer skincare launches across PanOxyl®, Blue Lizard®, StriVectin®, TL Advanced and Sarna®.

Q: Who are the clinicians presenting Revance booth talks? A: Scheduled presenters include Diane Berson, MD; Michael Gold, MD; Ava Shamban, MD; Jody Comstock, MD; and Suneel Chilukuri, MD, covering topics from injectable technique to microneedling and filler multilayering.

Q: Is DAXXIFY® approved for all cosmetic uses? A: DAXXIFY® is a prescription medicine approved for the temporary improvement of moderate to severe frown lines (glabellar lines) in adults. Clinicians must follow approved labeling and discuss off-label use with caution, supported by evidence and appropriate consent.

Q: What safety information should clinicians communicate about DAXXIFY®? A: Clinicians must inform patients about the risk of serious side effects, including problems with swallowing, speaking or breathing that can be life-threatening. The product may cause toxin effects distant from the injection site (muscle weakness, vision changes, voice changes, loss of bladder control). Do not administer if the patient has a history of allergies to botulinum toxin ingredients or prior allergic reactions to other botulinum toxins. DAXXIFY® dosing units are not comparable to other botulinum toxin products. Clinicians should collect comprehensive medical histories, report adverse events per Revance and FDA guidance, and maintain detailed treatment records.

Q: How can dermatology practices integrate Revance consumer products? A: Practices can order samples and retail SKUs, incorporate product trials into consultations, and recommend specific regimens tied to procedural care (e.g., medicated cleansers pre-microneedling, barrier creams post-resurfacing). Inventory planning, staff briefings on product indications and contraindications, and patient education materials will facilitate integration.

Q: What does the AIRE Health partnership mean for clinicians? A: The AIRE Health collaboration focuses on physician-led, technology-enabled brand interactions, including programming on ethical, practical and revenue models for physician-brand partnerships. Clinicians should use these discussions to refine disclosure practices, evaluate collaboration structures and ensure patient-centered engagement.

Q: Are booth samples and Blue Lizard scrub tops available for all attendees? A: Revance will distribute samples of new and hero SKUs throughout the conference and will offer Blue Lizard scrub tops for dermatologists during Exhibit Hall hours while supplies last.

Q: How should practices handle the non-interchangeable dosing units of DAXXIFY®? A: Document the exact product, dose, lot and treatment site in patient records. Educate staff on unit non-equivalence to avoid dosing errors when switching products. Follow product-specific dosing guidance and do not assume unit parity with other botulinum toxin formulations.

Q: Where can clinicians find more information after AAD? A: Clinicians can access additional information and corporate resources at Revance’s website. Post-conference materials, webinars and training sessions are commonly provided to expand on in-person AAD programming.

Revance’s appearance at AAD 2026 gathers several threads shaping modern dermatology: durable neuromodulation options, regulated microneedling platforms, layering filler techniques and the commercial logic of integrating consumer skincare into clinical pathways. For practices, the immediate task is practical: assess clinical evidence, train staff, update consent and inventory systems, and use patient trials to evaluate whether new products meet outcomes and practice economics. AAD provides the concentrated forum for making those determinations—Revance’s Booth #3732 is one of several industry touchpoints where those clinical decisions will begin to take shape.